A dual GLP-1/GDF15 agonist led to greater reductions in body weight, food intake, insulin, fasting glucose, and triglycerides compared to individual treatments (Zhang et al. 2023b), highlighting GDF15’s potential in obesity management. The gene discussed is GDF15; the disease is Obesity.